Institute of Pathology, Medical University of Graz, Graz, Austria.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
J Hepatol. 2017 Mar;66(3):610-618. doi: 10.1016/j.jhep.2016.11.011. Epub 2016 Nov 25.
BACKGROUND & AIMS: Few data exist on predictors of long-term prognosis in patients with alcoholic liver disease (ALD). Most studies have only assessed short-term prognosis in patients with advanced ALD. We aimed to assess the prognostic impact of clinical, biochemical and histological parameters on long-term prognosis in patients with early/compensated and decompensated ALD.
Consecutive patients (n=192) with biopsy-proven liver disease due to alcohol abuse were analyzed retrospectively. Prognostic factors were evaluated in patients with early/compensated ALD (n=60) and in patients with decompensated ALD (clinical decompensation and/or bilirubin >3mg/dl at entry) (n=132). Factors that predict long-term survival were identified using Cox regression models.
Liver-related mortality at 5years was 13% in early/compensated and 43% in decompensated ALD. In early/compensated ALD patients, long-term prognosis was determined by fibrosis stage, but not by clinical or biochemical variables. Severe fibrosis (F3/4) was present in 52% and had a major impact on 10-year mortality (F3/4: 45% vs. F0-2: 0%, p<0.001). In contrast, in decompensated patients, a combination of clinical features (sex), biochemical markers of liver failure (bilirubin, international normalized ratio [INR]), and histological features (pericellular fibrosis) predicted long-term survival. During follow-up, abstinence from alcohol was an important predictor of survival in both early/compensated and decompensated ALD.
Fibrosis stage is the main predictor of long-term survival in patients with early/compensated ALD, while clinical, biochemical and histological parameters predict survival in patients with decompensated disease. Promoting abstinence may improve survival in patients with both early and advanced ALD.
In this study, we evaluated long-term outcome in 192 patients with alcoholic liver disease who underwent liver biopsy: 60 patients with early disease (no symptoms) and 132 patients with advanced disease (jaundice, complications of cirrhosis). Importantly, half of the patients with 'early' disease already had severe fibrosis or cirrhosis on liver histology and dismal outcome (45% mortality at 10years). Abstinence from alcohol improved the prognosis in both early and advanced stages of the disease.
关于酒精性肝病(ALD)患者的长期预后预测因素的数据很少。大多数研究仅评估了晚期 ALD 患者的短期预后。我们旨在评估临床、生化和组织学参数对早期/代偿性和失代偿性 ALD 患者长期预后的预测作用。
回顾性分析了经活检证实的 192 例因酒精滥用导致的肝病患者。在早期/代偿性 ALD 患者(n=60)和失代偿性 ALD 患者(临床失代偿和/或入院时胆红素>3mg/dl)(n=132)中评估了预后因素。使用 Cox 回归模型确定预测长期生存的因素。
5 年时,早期/代偿性 ALD 患者的肝脏相关死亡率为 13%,失代偿性 ALD 患者的死亡率为 43%。在早期/代偿性 ALD 患者中,长期预后由纤维化分期决定,但不受临床或生化变量影响。严重纤维化(F3/4)占 52%,对 10 年死亡率有重大影响(F3/4:45% vs. F0-2:0%,p<0.001)。相比之下,在失代偿性患者中,临床特征(性别)、肝功能衰竭的生化标志物(胆红素、国际标准化比值[INR])和组织学特征(细胞周纤维化)的组合预测了长期生存。在随访期间,酒精戒断是早期/代偿性和失代偿性 ALD 患者生存的重要预测因素。
纤维化分期是早期/代偿性 ALD 患者长期生存的主要预测因素,而临床、生化和组织学参数则预测失代偿性疾病患者的生存。促进酒精戒断可能会改善早期和晚期 ALD 患者的生存。
非专业人士请谨慎阅读,译文仅供参考。